Haemophilia A with anti factor VIII – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:22:49 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Haemophilia A with anti factor VIII – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study looking at the safety of switching from emicizumab to denecimig in adults and adolescents with haemophilia A with or without inhibitors https://clinicaltrials.eu/trial/a-study-looking-at-the-safety-of-switching-from-emicizumab-to-denecimig-in-adults-and-adolescents-with-haemophilia-a-with-or-without-inhibitors/ Mon, 04 May 2026 08:05:50 +0000 https://clinicaltrials.eu/trial/a-study-looking-at-the-safety-of-switching-from-emicizumab-to-denecimig-in-adults-and-adolescents-with-haemophilia-a-with-or-without-inhibitors/ This study involves people with haemophilia A, a condition where blood does not clot properly because the body lacks enough of a specific clotting protein. This condition can occur with or without the presence of inhibitors, which are substances in the blood that can block the clotting protein from working. The study will use a medication called denecimig, also known by its code name NNC0365-3769 or Mim8, which is given as an injection under the skin. Participants will be switching from their current medication called emicizumab to the study medication.

The purpose of this study is to look at how safe it is for people with haemophilia A to switch from emicizumab to Mim8. The study will observe what happens during the time when emicizumab is leaving the body while people are starting treatment with Mim8. This includes watching for any unwanted effects that might occur during this switch.

During the study, participants will receive Mim8 injections under the skin for up to 26 weeks. They will need to attend regular visits and keep track of their experiences using an electronic diary. The study will also ask participants to complete questionnaires about how they find using the injection device and how the treatment affects their daily life. The study involves adults and adolescents aged 12 years and older who have been taking emicizumab for at least 8 weeks and who have decided with their doctor to stop taking emicizumab.

]]> A study of long-term safety and effectiveness of denecimig in people with haemophilia A with or without inhibitors https://clinicaltrials.eu/trial/a-study-of-long-term-safety-and-effectiveness-of-denecimig-in-people-with-haemophilia-a-with-or-without-inhibitors/ Thu, 30 Apr 2026 13:08:43 +0000 https://clinicaltrials.eu/trial/a-study-of-long-term-safety-and-effectiveness-of-denecimig-in-people-with-haemophilia-a-with-or-without-inhibitors/ This study involves haemophilia A, a bleeding disorder where the blood does not clot properly because it lacks enough of a protein called clotting factor VIII. People with this condition may experience prolonged bleeding after injuries or surgery, and sometimes bleeding can occur without any obvious cause, particularly into joints and muscles. Some people with haemophilia A also develop inhibitors, which are proteins made by the body’s immune system that block the clotting factor treatments from working properly. The study uses denecimig, also known as Mim8 or NNC0365-3769, which is given as an injection under the skin. This medication is a type of antibody that helps the blood clot by bringing together two clotting factors in the blood.

The purpose of the study is to learn about the long-term safety of Mim8 when used as a preventive treatment in people with haemophilia A, whether or not they have inhibitors. The study will look at what side effects occur over time and how well the treatment works to prevent bleeding episodes. Participants joining this study are already taking part in or have completed other research studies with Mim8, and this study allows them to continue receiving the treatment for a longer period. Some very young participants who have not yet received much treatment for haemophilia A may also join the study.

During the study, participants will receive regular injections of Mim8 under the skin for up to 262 weeks, which is about five years. Throughout this time, they will attend regular clinic visits where doctors will check their health, take blood samples to measure the level of medication in the blood and look for any antibodies the body might make against the treatment, and ask about any bleeding episodes or side effects. Participants or their caregivers will keep a diary to record any bleeding episodes, treatments used, and any problems with the injection device. The study will also look at how easy the injection device is to use for those participants who use it.

]]> Study on How Concizumab Works for Patients with Hemophilia A or B with Inhibitors https://clinicaltrials.eu/trial/study-on-how-concizumab-works-for-patients-with-hemophilia-a-or-b-with-inhibitors/ Wed, 29 Apr 2026 14:57:21 +0000 https://clinicaltrials.eu/trial/study-on-how-concizumab-works-for-patients-with-hemophilia-a-or-b-with-inhibitors/ This clinical trial is focused on studying the effects of a medication called concizumab in people with hemophilia A or hemophilia B who have developed inhibitors. Hemophilia is a condition where the blood does not clot properly, leading to excessive bleeding. Inhibitors are antibodies that can develop in some patients, making standard treatments less effective. The medication being tested, concizumab, is given as a solution for injection using a pen-injector device.

The purpose of the study is to see how well concizumab works in reducing the number of bleeding episodes compared to no regular preventive treatment. Participants will be divided into groups, with some receiving concizumab and others receiving their usual on-demand treatment. The study will last for several months, during which participants will receive regular injections of concizumab and be monitored for any changes in their bleeding patterns.

Throughout the study, researchers will collect information on the number of bleeding episodes, any side effects, and how the participants feel physically. This information will help determine if concizumab is a safe and effective treatment option for people with hemophilia A or B with inhibitors. The study aims to provide valuable insights into managing this condition and improving the quality of life for those affected.

]]> Study on the Safety and Effectiveness of SerpinPC for Patients with Severe Hemophilia A or B https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-serpinpc-for-patients-with-severe-hemophilia-a-or-b/ Wed, 29 Apr 2026 14:23:49 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-serpinpc-for-patients-with-severe-hemophilia-a-or-b/ This clinical trial is focused on studying the effects of a treatment called SerpinPC for individuals with Severe Hemophilia A or Moderately Severe to Severe Hemophilia B. Hemophilia is a condition where the blood does not clot properly, leading to excessive bleeding. The treatment being tested, SerpinPC, is a solution for injection that contains a modified form of a protein called human alpha-1 proteinase inhibitor. This study aims to evaluate how effective and safe SerpinPC is when given as a regular preventive treatment through subcutaneous injection, which means it is injected under the skin.

The purpose of the study is to assess the efficacy and safety of SerpinPC in people with these types of hemophilia. Participants in the study will receive the treatment over a period of time, and their health will be monitored to see how well the treatment works in reducing bleeding episodes. The study will also look at the overall health and quality of life of the participants while they are receiving the treatment.

Throughout the study, participants will be observed for any changes in their condition, and the number of bleeding episodes they experience will be recorded. The study will help determine if SerpinPC can be a beneficial treatment option for those living with Severe Hemophilia A or Moderately Severe to Severe Hemophilia B. The trial is designed to gather important information that could lead to improved care and management of these conditions in the future.

]]>